Ph III Study of Sacituzumab Govitecan + Pembro v. Dr. Choice + Pembro in Pts w/ Trip-Neg Breast Ca

Cancer
Ritesh Parajuli
A Randomized, Open-Label, Phase III Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced, Inoperable, or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1
Breast

Study Description

The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) and pembrolizumab versus treatment of physician's choice (TPC) and pembrolizumab in participants with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors express programmed cell death ligand 1 (PD-L1).

Eligibility

-Participants must be at least 18 years of age

-Participants must have locally advanced, inoperable, or metastatic triple-negative breast cancer (TNBC) who have not received previous systemic therapy for advanced disease and whose tumors are programmed cell death ligand 1 (PD-L1) positive at screening.

-Male and female participants of childbearing potential who engage in heterosexual intercourse must agree to use protocol-specified method(s) of contraception.

-Participants who are pregnant or lactating

-Participants who have received prior therapy with an agent directed to another stimulatory or coinhibitory T-cell receptor.

-Participants who have active serious infection requiring antibiotics.

A female nurse attentively holds a tablet, ready to assist with patient care and medical information.

Interested in Participating in this Trial?

Thank you for your interest with our team.

One of our specialists will be in contact with you soon.